Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With Pyrifazimine (TBI-166)

NCT04670120 is registered in ClinicalTrials.gov with Beijing Chest Hospital as lead sponsor.

NCT NCT04670120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04670120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With Pyrifazimine (TBI-166)
Lead sponsor
Beijing Chest Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2021
Completion date
December 31, 2021
Enrollment
56 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sensitive pulmonary tuberculosis